drugset / Trial / NCT03377491

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

NCT03377491 ↗

Phase 3 Completed 571 enrolled NovoCure Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Timeline

Start
2018-05-10
Primary completion
2024-10-16
Completion
2024-10-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous
Background Nab-paclitaxel Small molecule 125 mg/m2 Intravenous